Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Global Cord Blood's 3-Year RORE % for the quarter that ended in Mar. 2022 was 0.00%.
The industry rank for Global Cord Blood's 3-Year RORE % or its related term are showing as below:
CORBF's 3-Year RORE % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -7.89 * Ranked among companies with meaningful 3-Year RORE % only.
Global Cord Blood (OTCPK:CORBF) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Global Cord Blood 3-Year RORE % Related Terms
Global Cord Blood 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Global Cord Blood's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CORBF vs PRE, LMDX, NOTV: 3-Year RORE % Comparison
For the Diagnostics & Research subindustry, Global Cord Blood's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Global Cord Blood 3-Year RORE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Global Cord Blood's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Global Cord Blood's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2022 and 3-year before.
Global Cord Blood (CORBF) has a 3-Year RORE % of 0.00 as of Mar. 2022. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Global Cord Blood and its competitors.
Is Global Cord Blood's 3-Year RORE % too high?
Global Cord Blood's current 3-Year RORE % is 0.00. Overall, Global Cord Blood has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Global Cord Blood's 3-Year RORE % compare to PRE and LMDX?
Global Cord Blood's 3-Year RORE % of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Global Cord Blood and its competitors. Global Cord Blood's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Global Cord Blood stock overvalued right now?
Global Cord Blood (CORBF) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. Global Cord Blood's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Global Cord Blood (CORBF), the current 3-Year RORE % is 0.00 as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Global Cord Blood Corp provides cord blood banking services. The company provides cord blood processing and storage services for expectant parents interested in capturing the evolving medical treatments and technologies such as cord blood transplants. The company generates all of its revenues by providing subscribers with processing services, which consist of the testing and processing of cord blood units, and storage services, which consist of the storage of cord blood units in its facilities.
12GF Score
Get the complete analysis for CORBF
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CORBF has been successfully added to your 
